419 filings
Page 2 of 21
8-K
iuohw4yg5 u7k64x5b
3 Oct 23
Shareholder Nominations Pursuant to Exchange Act Rule 14a-11
4:05pm
8-K
v25tarwups7dzqwg jz2
26 Sep 23
Avalo Therapeutics Successfully Eliminates $35 Million Debt Paving the Way for Future Growth and Innovation
7:04am
8-K
ttf63
13 Sep 23
Entry into a Material Definitive Agreement
4:03pm
8-K
gw36ms7
13 Sep 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
9:12am
8-K
unvm6plognfgnw6g bi
12 Sep 23
Avalo Enters into Agreement to Divest AVTX-800 Series
7:10am
8-K
x7z quvv2n03ls3oi
11 Sep 23
Other Events
7:22am
8-K
eagsyu
14 Aug 23
Entry into a Material Definitive Agreement
4:23pm
8-K
fxhkz 9g2
8 Aug 23
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard
4:11pm
8-K
77wj5
7 Aug 23
Entry into a Material Definitive Agreement
5:27pm
424B5
bdv 8acntegke
7 Aug 23
Prospectus supplement for primary offering
5:26pm
8-K
bd4vyjk5r
3 Aug 23
Avalo Reports Second Quarter 2023 Financial Results and Provides Business Updates
7:01am
8-K
mpts2e3a5ukw
21 Jul 23
Entry into a Material Definitive Agreement
8:25am
8-K
klqqc7ccm
26 Jun 23
Avalo Announces Topline Data from Phase 2 PEAK Trial for AVTX-002 (quisovalimab) in Patients with Non-Eosinophilic Asthma
7:03am
8-K
njuhfsys5 ac4q
2 Jun 23
Entry into a Material Definitive Agreement
7:05am
S-8
9vzzcx2h
4 May 23
Registration of securities for employees
5:10pm
424B5
me2k4pfhbz 69ij
4 May 23
Prospectus supplement for primary offering
5:04pm
8-K
2bgtxn
4 May 23
Entry into a Material Definitive Agreement
4:56pm